osgemcitabine palabenamide API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for osgemcitabine palabenamide API 840506-29-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of osgemcitabine palabenamide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- osgemcitabine palabenamide
- Synonyms:
- ACELARIN , BENZYL (2S)-2-((((2R,3R,5R)-5-(4-AMINO-2-OXO-PYRIMIDIN-1-YL)-4,4-DIFLUORO-3-HYDROXY-TETRAHYDROFURAN-2-YL)METHOXY-PHENOXY-PHOSPHORYL)AMINO)PROPANOATE , Fosgemcitabine palabenamide, p(rs)- , L-ALANINE, N-(2'-DEOXY-2',2'-DIFLUORO-P-PHENYL-5'-CYTIDYLYL)-, PHENYLMETHYL ESTER , L-Alanine, N-[[P(S)]-2?-deoxy-2?,2?-difluoro-P-phenyl-5?-cytidylyl]-, phenylmethyl ester , N-[[P(S)]-2?-deoxy-2?,2?-difluoro-P-phenyl-5?-cytidylyl]-L-alanine phenylmethyl ester
- Cas Number:
- 840506-29-8
- DrugBank number:
- DB15057
- Unique Ingredient Identifier:
- XCL1K2T28K
General Description:
osgemcitabine palabenamide, identified by CAS number 840506-29-8, is a notable compound with significant therapeutic applications. NUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
Classification:
osgemcitabine palabenamide belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2, classified under the direct parent group Pyrimidine 2'-deoxyribonucleosides. This compound is a part of the Organic compounds, falling under the Nucleosides, nucleotides, and analogues superclass, and categorized within the Pyrimidine nucleosides class, specifically within the Pyrimidine 2'-deoxyribonucleosides subclass.
Categories:
osgemcitabine palabenamide is categorized under the following therapeutic classes: Antineoplastic Agents, Cytosine Nucleotides, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Pyrimidine Nucleotides, Pyrimidines, Ribonucleotides. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
osgemcitabine palabenamide is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
